Psychedelics
Joël Brierre Calls To Those Seeking Transformation – Podcast Episode #24
On the season three premiere of the Psychedelic Invest Podcast, host Bruce Eckfeldt is joined by Joël Brierre. Joel Brierre is the Founder and CEO of…
On the season three premiere of the Psychedelic Invest Podcast, host Bruce Eckfeldt is joined by Joël Brierre.
Joel Brierre is the Founder and CEO of the psychedelic wellness companies Kaivalya Kollectiv and Tandava Retreats, as well as co-founder of the 5-MeO-DMT education and training platform, F.I.V.E.. Joel has been a leader in the modern psychedelic movement, specifically in the realm of 5-MeO-DMT and the Bufo Alvarius toad, and has spent years helping to create safe and effective protocols around this molecule. With a passion for preparation and integration protocols, Joel and his team are involved in everything from clinical research and trainings to experiential retreats in Mexico and Jamaica.
Listen To All Episodes on YouTube
All season two episodes are now available on YouTube. Check out the Psychedelic Invest YouTube channel to listen to the entire season without a subscription.
More To Come for Season Three
We have a great season of another ten full episodes planned out for your enjoyment.
If you just found out about the podcast, we encourage you to check out the Psychedelic Invest Podcast page or subscribe to the show on your favorite audio platform to binge and catch up.
The Transcription is Coming Soon
-
Psychedelics1 week ago
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
-
Psilocybin1 week ago
California advances bill for psychedelics centers
-
Psilocybin5 days ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
Psychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics1 week ago
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
-
Psychedelics4 days ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics5 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics5 days ago
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research